STOCK TITAN

Quince Therapeutics (QNCX) 10-K Filings

QNCX NASDAQ

Ticker history: QNCX became IRLA (IRulya Therapeutics Inc.) on .

Here are the 10-K annual reports from Quince Therapeutics, Inc. (QNCX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow QNCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNCX filings page.

Rhea-AI Summary

Quince Therapeutics, Inc. reports that its lead asset eDSP failed to meet primary and key secondary endpoints in the pivotal NEAT Phase 3 trial for A‑T, leading the company to discontinue all development of eDSP and other product candidates. With no active pipeline and limited resources, Quince is now primarily focused on preserving cash and exploring strategic alternatives, especially a potential reverse merger, for which it has hired LifeSci Capital as exclusive financial advisor.

The company flags substantial doubt about its ability to continue as a going concern and plans to seek additional equity or debt financing, including potential sales of common stock under an at‑the‑market agreement. Quince also discloses Nasdaq notices for noncompliance with minimum bid price and market value requirements and warns that delisting could occur. As of December 31, 2025, Quince had $17.8 million in cash, cash equivalents and short‑term investments, an accumulated deficit of $460.5 million, and a net loss of $84.0 million for 2025, while continuing to evaluate restructuring options and potential asset sales.